Get the Stockscreener App
1.025
0.57%
-0.005
Ocugen Inc stock is traded at $1.025, with a volume of 883.95K.
It is down -0.57% in the last 24 hours and down -4.29% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.03
Open:
$1.02
24h Volume:
883.95K
Relative Volume:
0.17
Market Cap:
$299.61M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.7963
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
+2.57%
1M Performance:
-4.29%
6M Performance:
+42.65%
1Y Performance:
-21.82%
1-Day Range:
$1.02
$1.04
1-Week Range:
$0.96
$1.0693
52-Week Range:
$0.515
$1.40
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.025 | 301.07M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.94 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.20 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.74 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
650.63 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.97 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Will Ocugen Inc. Benefit From Broader Market BounceJuly 2025 Review & High Win Rate Trade Alerts - newsyoung.net
Is Ocugen Inc. part of any ETFMarket Weekly Review & Safe Entry Momentum Stock Tips - newsimpact.co.kr
Can Ocugen Inc. benefit from deglobalization2025 Top Gainers & Verified Swing Trading Watchlists - sundaytimes.kr
Ocugen reports EMA positive advice for acceptability of OCU410ST - MSN
EMA's CHMP Gives Ocugen the Green Light to Submit MAA for OCU410ST Based on GARDian3 Trial - CGTLive®
How to contact the Daily Bulletin - FinancialContent
Ocugen's Strategic Advancements and Financial Positioning Support Buy Rating - AInvest
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - Ocugen
Acuity Inc. shares rise 1.01% premarket after Ocugen, Inc. receives positive scientific advice. - AInvest
Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy - MarketScreener
Ocugen, Inc. Announces Positive Scientific Advice from the Europ - GuruFocus
Ocugen gets EMA backing for single trial of Stargardt disease therapy - Investing.com Australia
Ocugen, Inc. Announces Positive Scientific Advice from the - GlobeNewswire
Ocugen's Stargardt Disease Treatment Gets Fast-Track to EU Approval with Single Trial Plan - Stock Titan
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Janus Henderson Group Plc shares rise 1.98% after-hours following $20 million investment in Ocugen, Inc. - AInvest
Ocugen Secures $20 Million in Direct Offering with Janus Henderson - MSN
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen raises $20 million in direct offering to Janus Henderson - Investing.com
Ocugen raises $20 million in direct offering to Janus Henderson By Investing.com - Investing.com Australia
Ocugen Secures $20 Million in Registered Direct Offering, Extending Cash Runway into 2026 - AInvest
Ocugen secures crucial $20M funding from Janus Henderson, could unlock additional $30M from warrants - Stock Titan
Ocugen Announces $20M Securities Purchase Agreement to Bolster Gene Therapy Programs - AInvest
Ocugen Announces $20M Securities Purchase Agreement - TipRanks
Ocugen Announces $20 Million Registered Direct Offering of Common Stock and Warrants. - AInvest
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Will Ocugen Inc. outperform the market in YEARPre-Earnings Rally Picks - kangso.co.kr
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen raises $20 million in registered direct offering - Investing.com
Ocugen Raises $20M in Direct Offering of Common Stock and Warrants - AInvest
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
Should I hold or sell Ocugen Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Ocugen Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):